A commercial assay that measures eMTBR-tau may be an alternative to tau PET imaging in diagnosing Alzheimer’s disease, according to data presented at the Alzheimer’s Association International Conference.Definitive diagnoses require evidence of amyloid plaques and tau neurofibrillary tangles, Alamar Biosciences said in a press release. Blood tests can measure p-tau217, which indicates amyloid pathology.But many patients with accumulated amyloids do…
Source: Healio News
